- Home
- ENTG vs GMAB Comparison
ENTG vs GMAB Comparison
Compare ENTG & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTG
- GMAB
- Stock Information
- Founded
- ENTG 1966
- GMAB 1999
- Country
- ENTG United States
- GMAB Denmark
- Employees
- ENTG N/A
- GMAB N/A
- Industry
- ENTG Plastic Products
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- ENTG Industrials
- GMAB Health Care
- Exchange
- ENTG Nasdaq
- GMAB Nasdaq
- Market Cap
- ENTG 11.7B
- GMAB 13.2B
- IPO Year
- ENTG 2000
- GMAB N/A
- Fundamental
- Price
- ENTG $87.76
- GMAB $24.65
- Analyst Decision
- ENTG Strong Buy
- GMAB Buy
- Analyst Count
- ENTG 10
- GMAB 6
- Target Price
- ENTG $107.30
- GMAB $37.60
- AVG Volume (30 Days)
- ENTG 3.3M
- GMAB 1.2M
- Earning Date
- ENTG 07-30-2025
- GMAB 08-07-2025
- Dividend Yield
- ENTG 0.49%
- GMAB N/A
- EPS Growth
- ENTG 60.99
- GMAB 77.72
- EPS
- ENTG 1.95
- GMAB 21.62
- Revenue
- ENTG $3,223,108,000.00
- GMAB $3,646,881,232.00
- Revenue This Year
- ENTG $0.64
- GMAB $21.64
- Revenue Next Year
- ENTG $9.41
- GMAB $15.57
- P/E Ratio
- ENTG $45.01
- GMAB $11.06
- Revenue Growth
- ENTG N/A
- GMAB 32.97
- 52 Week Low
- ENTG $60.75
- GMAB $17.24
- 52 Week High
- ENTG $119.95
- GMAB $27.94
- Technical
- Relative Strength Index (RSI)
- ENTG 62.75
- GMAB 67.82
- Support Level
- ENTG $77.01
- GMAB $21.00
- Resistance Level
- ENTG $81.75
- GMAB $22.90
- Average True Range (ATR)
- ENTG 3.15
- GMAB 0.43
- MACD
- ENTG 1.15
- GMAB 0.24
- Stochastic Oscillator
- ENTG 94.36
- GMAB 95.31
About ENTG Entegris Inc.
Entegris is a leading supplier of purification solutions and advanced materials. The vast majority of sales are to the semiconductor industry. The majority of revenue comes from semiconductor fabricators, but the company sells to all areas of the semiconductor manufacturing supply chain including equipment and engineering, chemicals and materials, and distributors. Entegris specializes in materials science and materials purity, both of which are crucial in the semiconductor manufacturing process.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.